Icotrokinra

Icotrokinra is a macrocyclic peptide that functions as a selective, competitive antagonist of the interleukin-23 receptor (IL-23R). Unlike approved monoclonal antibodies that neutralize the IL-23 cytokine ligand (such as guselkumab, risankizumab, and tildrakizumab), icotrokinra acts directly at the receptor, binding IL-23R with extraordinary potency (dissociation constant: 7 picomolar).

The IL-23 signaling axis is a central driver of immune-mediated inflammatory disease. Under normal conditions, IL-23 binds the IL-23R/IL-12Rβ1 heterodimeric receptor complex on T helper cells, promoting the expansion and survival of Th17 cells. These cells subsequently release IL-17A, IL-17F, IL-22, and interferon-gamma (IFN-γ), which collectively drive the keratinocyte hyperproliferation, dermal infiltration, and plaque formation characteristic of psoriasis.

By occupying IL-23R at picomolar concentrations, icotrokinra blocks all downstream IL-23-induced signaling and cytokine release. Pharmacodynamic studies from the Phase 2b FRONTIER program demonstrated dose-dependent reductions in serum IL-17A, IL-17F, IL-22, and the skin biomarker beta-defensin-2 (BD-2), which correlated strongly with PASI improvement (R = -0.6 for BD-2). Proteomic analysis using the Olink Explore HT platform found that only 11 of 5,420 circulating proteins were significantly downregulated, 8 of which were directly relevant to the IL-23/IL-17 pathway, indicating highly selective immunomodulation without broad immunosuppression.

• Oral bioavailability: approximately 0.1-0.3% in preclinical species, yet adequate plasma exposure is achieved without absorption enhancers. • Half-life: approximately 12 hours, reaching steady state in about 3 days. • Minimal hepatic metabolism; primary elimination is fecal excretion of unchanged drug. No significant CYP450 enzyme inhibition or induction has been observed in vitro.

Human evidence supporting icotrokinra spans Phase 2 dose-ranging studies, four Phase 3 randomized trials involving approximately 2,500 patients, and a 2026 systematic review with meta-analysis.

Phase 2 (FRONTIER-1 and FRONTIER-2): FRONTIER-1 was a randomized, double-blind, placebo-controlled dose-ranging trial (n = 248 for serum analysis) testing doses from 25 mg once daily to 100 mg twice daily. At the highest dose (100 mg BID), 79% of participants achieved PASI 75 and 40% achieved complete skin clearance (PASI 100) at Week 16, versus 9% PASI 75 for placebo. FRONTIER-2 extended follow-up to 52 weeks, confirming durable responses with no new safety signals.

Phase 3 ICONIC program (trials PSO-1 through PSO-4, registered as ICONIC-LEAD NCT06095115, ICONIC-ADVANCE 1 NCT06143878, ICONIC-ADVANCE 2 NCT06220604, and ICONIC-TOTAL NCT06095102): In ICONIC-LEAD, conducted in adults and adolescents aged 12 years and older, 65% achieved IGA 0/1 and 50% achieved PASI 90 at Week 16 versus 8% and 4% for placebo, respectively. By Week 24 these improved to 74% IGA 0/1 and 65% PASI 90. In the head-to-head ICONIC-ADVANCE 1 and 2 studies, icotrokinra demonstrated superiority over the oral TYK2 inhibitor deucravacitinib for skin clearance at Weeks 16 and 24, with approximately 70% achieving IGA 0/1 and 55-57% achieving PASI 90. ICONIC-TOTAL showed 77% of patients with genital psoriasis and 66% with scalp psoriasis achieved clear or almost clear skin.

A 2026 systematic review and meta-analysis (Frontiers in Immunology, n = 1,951 across five RCTs) reported pooled risk ratios for icotrokinra versus placebo: IGA 0/1, RR 7.27 (95% CI 5.62-9.40); PASI 90, RR 13.82 (95% CI 8.75-21.84); PASI 100, RR 31.65 (95% CI 12.56-79.76); all p less than 0.001. The authors applied GRADE methodology and rated evidence certainty as moderate to high for most efficacy outcomes, noting Trial Sequential Analysis indicated the required information size has not yet been reached for definitive conclusions.

Ongoing studies are evaluating icotrokinra in psoriatic arthritis (ICONIC-PsA 1 and 2), ulcerative colitis (ICONIC-UC), and Crohn's disease (ICONIC-CD). A Phase 2b ulcerative colitis study (ANTHEM-UC, n = 252) reported a 63.5% clinical response rate at Week 12 at the highest dose versus 27% for placebo, though an indication approval for inflammatory bowel disease had not been issued as of mid-2026.

The FDA-approved dose for icotrokinra (brand name Icotyde) in moderate-to-severe plaque psoriasis is 200 mg orally once daily. Administration instructions are specific and important to follow due to a marked food effect.

Timing and food interaction: The tablet should be taken upon waking, on an empty stomach, with water. Patients must wait at least 30 minutes after taking the dose before eating any food. A high-fat meal reduces the drug's area under the curve (AUC) by 43% and peak concentration (Cmax) by 59%, which could meaningfully reduce therapeutic exposure.

Formulation: The tablet should be swallowed whole and must not be crushed, split, or chewed. For patients who have difficulty swallowing, the tablet may be dispersed in at least 120 mL of water and administered within 15 minutes of dispersal.

Patient population: Indicated for adults and pediatric patients 12 years of age and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. No dose adjustment is specified for elderly patients or those with mild renal impairment. In patients with moderate to severe renal impairment (eGFR less than 60 mL/min per 1.73 m²), drug exposure increases 2.47 to 2.78-fold; the prescribing information recommends monitoring for adverse reactions in this population, though no dose reduction is mandated at this time.

Dosing in the Phase 2 program tested multiple regimens including 25 mg once daily, 50 mg once daily, 100 mg once daily, and 100 mg twice daily. The 200 mg once-daily schedule approved for Phase 3 and commercial use reflects pharmacokinetic optimization for once-daily convenience.

This information is provided for educational purposes only. Icotrokinra is a prescription medication that must be prescribed and supervised by a licensed healthcare provider. Nothing here constitutes medical advice.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

No formal combination therapy studies pairing icotrokinra with other systemic agents have been published as of mid-2026. The ICONIC Phase 3 trials were designed as monotherapy studies comparing icotrokinra against placebo or against deucravacitinib as an active oral comparator. The FDA prescribing label does not address combination regimens.

The active comparator trial ICONIC-ASCEND (NCT06934226) is comparing icotrokinra to ustekinumab, a biologic IL-12/23 inhibitor, in a head-to-head design; results from this trial were not yet published by mid-2026.

From a mechanistic standpoint, clinicians have noted that icotrokinra's receptor-level blockade of IL-23 signaling is conceptually compatible with agents targeting different upstream or downstream pathways. Some expert commentary has suggested theoretical utility of combining an IL-23R antagonist with topical agents (corticosteroids, calcipotriene, or phosphodiesterase-4 inhibitors) in patients seeking enhanced local disease control, but this is based solely on mechanism and clinical intuition rather than any controlled data; it should be regarded as anecdotal.

The prescribing information explicitly states that live vaccines should be avoided during treatment, and physicians are advised to complete all age-appropriate vaccinations prior to initiation. No significant drug-drug interactions were identified in in vitro studies, and icotrokinra is neither a substrate nor an inhibitor of major CYP450 enzymes or drug transporters, which reduces the theoretical risk of pharmacokinetic interactions if used alongside other oral medications.

Icotrokinra is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Icotrokinra demonstrated a highly favorable safety profile across the ICONIC Phase 3 program, with overall adverse event rates numerically indistinguishable from placebo through Week 16.

Common adverse reactions occurring in at least 1% of treated patients through Week 16 (based on the FDA label): headache 4.1%, nausea 1.2%, cough 1.2%, fungal infection 1.1%, and fatigue 1.0%. Adverse reaction rates for icotrokinra-treated patients were within 1.1 percentage points of placebo. Rates of serious adverse events were lower in icotrokinra-treated patients than placebo (RR 0.71 in pooled meta-analysis). No new safety signals were identified through Week 52 of the ICONIC trials.

Serious adverse reactions occurring at less than 1% included gastritis, abdominal discomfort, and one fatal case of upper gastrointestinal bleeding; causality to the drug was not established in available reports.

Infections: Serious infections occurred in 0.2% of icotrokinra-treated patients versus 0.4% of placebo patients through Week 16. Treatment should be avoided in patients with active, clinically important infections. Clinicians should consider tuberculosis (TB) evaluation prior to initiating therapy based on clinical judgment, and patients should be monitored for active TB signs and symptoms during and after treatment.

Immunizations: Live vaccines should not be administered during treatment. All age-appropriate vaccinations should be completed according to current immunization guidelines before starting icotrokinra.

There are no listed contraindications in the FDA prescribing information.

Renal impairment: Exposure increases approximately 2.5 to 2.8-fold in moderate to severe renal impairment (eGFR below 60 mL/min); monitoring for adverse reactions is recommended in this group.

Pregnancy and lactation: Reproductive toxicology studies in rabbits at 157 times the maximum recommended human dose showed maternal weight loss and increased incidence of fetal fused ribs. Human data are insufficient to evaluate risk of major birth defects or miscarriage. Icotrokinra was detected in the plasma of nursing rat pups, but it is unknown whether it appears in human breast milk. A pregnancy registry is available (1-800-526-7736).

Pediatric patients 12 years and older (at least 40 kg) showed an adverse reaction profile consistent with the adult population.